Clinical Trials Browser

Erlotinib Hydrochloride × Head & Neck × 1 year × Clear all

NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00076310 2026-04-15

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase 2 Active not recruiting

50 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT05827614 2026-01-23

POTENTIATE

Phase 1 Active not recruiting

85 enrolled

BreastHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Leiomyosarcoma, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01927744 2025-11-26

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Phase 2 Completed

55 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00954226 2025-09-05

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Phase 1 Completed

48 enrolled

Head & Neck

Salivary Gland Neoplasms